Raeisi Farzaneh, Mahmoudi Esmaeil, Dehghani-Samani Mina, Hosseini Seyedeh Sahar Ebrahimi, Ghahfarrokhi Ameneh Mehri, Arshi Asghar, Forghanparast Kayvan, Ghazanfari Samaneh
Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Mol Ther Oncolytics. 2020 Jan 23;16:230-237. doi: 10.1016/j.omto.2020.01.004. eCollection 2020 Mar 27.
Over the past decade, studies on microRNA (miRNA) and cancer quickly became known. miRNAs are small non-coding RNAs that play a vital role in regulation of gene expression. In the present study, the expression of miR-27b, miR-29a, and miR-155, their prognostic roles, and their potential targets in chronic lymphocytic leukemia (CLL) and breast cancer (BC) by qRT-PCR were investigated. In two case-control studies, qRT-PCR was used to analyze the peripheral blood serum of 15 CLL patients and tissue samples of 15 BC patients for the expression of miR-27b, miR-29a, and miR-155. miRNA expression levels were calculated using the qRT-PCR method. The results revealed a significant increase in the expression of all miRNAs in patients with BC and CLL compared with respective healthy groups (p < 0.001). In BC patients, there was a significant difference between the expression of miR-155 and miR-29a (p < 0.05), miR-155 and miR-27b (p < 0.01), and miR-27b and miR-29a (p < 0.001). In CLL patients, a significant difference between expression of both miR-27b and miR-29a compared with expression of miR-155 (p < 0.001) was found. Furthermore, a significant association between miR-155 and prevascular invasion was found. Significantly, elevated circulating miRNAs were shown to be BC specific and could differentiate BC tissues from the controls. It was demonstrated that miRNAs used in this study and their expression profiles can be developed as biomarkers for early diagnosis and prognosis of CLL and BC. Further studies utilizing a larger test group of patients would provide identification of miRNAs as key players in intercellular interactions.
在过去十年中，关于微小RNA（miRNA）与癌症的研究迅速为人所知。miRNA是一类小的非编码RNA，在基因表达调控中发挥着至关重要的作用。在本研究中，通过定量逆转录聚合酶链反应（qRT-PCR）研究了miR-27b、miR-29a和miR-155在慢性淋巴细胞白血病（CLL）和乳腺癌（BC）中的表达、它们的预后作用及其潜在靶点。在两项病例对照研究中，使用qRT-PCR分析了15例CLL患者的外周血血清和15例BC患者的组织样本中miR-27b、miR-29a和miR-155的表达。采用qRT-PCR方法计算miRNA表达水平。结果显示，与各自的健康组相比，BC和CLL患者中所有miRNA的表达均显著增加（p < 0.001）。在BC患者中，miR-155与miR-29a的表达之间存在显著差异（p < 0.05），miR-155与miR-27b的表达之间存在显著差异（p < 0.01），miR-27b与miR-29a的表达之间存在显著差异（p < 0.001）。在CLL患者中，发现miR-27b和miR-29a的表达与miR-155的表达之间存在显著差异（p < 0.001）。此外，发现miR-155与血管前浸润之间存在显著关联。值得注意的是，循环miRNA水平升高显示为BC特异性的，并且可以将BC组织与对照区分开来。结果表明，本研究中使用的miRNA及其表达谱可作为CLL和BC早期诊断和预后的生物标志物。利用更大的患者测试组进行进一步研究将确定miRNA作为细胞间相互作用中的关键参与者。
